Guideline position, pivotal evidence, effect sizes, negative findings — pediatric persistent asthma home monitoring

1. Summary

This report picks up the gap the domain dossier named but did not close: what NAEPP's own guideline text says about peak-flow monitoring specifically, and what the pediatric-specific pivotal trial evidence — effect sizes, and where they exist, negative findings — actually shows, as distinct from the device-accuracy and technology-landscape literature the dossier already covers. NAEPP's EPR-3 guideline treats peak-flow monitoring as a recommendation for a subgroup, not a default, and the 2020 NAEPP focused update left that specific guidance untouched. The pediatric trial evidence that exists shows a consistent split: home peak-flow feedback and electronic adherence-monitoring interventions in children reliably move process measures — lung function, inhaled-corticosteroid adherence, perception of airflow limitation — but the evidence on hard outcomes (acute-care visits, exacerbations, asthma control) is either null or, in one pediatric randomized trial, moves in the direction opposite to what a monitoring-device value proposition would want. Every quantitative finding below rests on a single trial or review unless the text says otherwise, and is marked accordingly.

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

Guideline position: peak-flow monitoring is a subgroup recommendation, not a default

NAEPP's Expert Panel Report 3 (EPR-3, 2007) is still the operative US guideline text on this specific question. The 2020 NAEPP focused update revised six priority topics — FeNO testing, indoor allergen mitigation, intermittent inhaled corticosteroids, long-acting muscarinic antagonists, allergen immunotherapy, and bronchial thermoplasty — across three pediatric/adult age bands (0-4, 5-11, 12+), and states of itself that it is "not a complete revision of EPR-3" and that "important aspects of care, such as asthma education (including inhaler technique) and assessment tools for asthma control, adherence, and other factors, are not covered" [2] [single-source]. Home monitoring method is one of the topics it left alone.

EPR-3's own text treats peak-flow monitoring and symptom monitoring as broadly interchangeable for most patients, but names specific subgroups for whom peak-flow monitoring is recommended rather than optional:

"Either peak flow monitoring or symptom monitoring, if taught and followed correctly, may be equally effective" (Evidence B) [1] [single-source]

"Whether peak flow monitoring, symptom monitoring, or a combination of approaches is used, self-monitoring is important to the effective self-management of asthma" (Evidence A) [1] [single-source]

The Expert Panel recommends considering daily peak-flow monitoring specifically for "patients who have moderate or severe persistent asthma" (Evidence B), "patients who have a history of severe exacerbations" (Evidence B), and "patients who poorly perceive airflow obstruction and worsening asthma" (Evidence D) — not for persistent asthma generally [1] [single-source]. The same text also flags "decreased utility [of peak-flow measurement] in preschool children," a caveat that sits at the younger edge of, but does not exclude, the 5-17 population this domain targets [1] [single-source].

Pivotal evidence: the one pediatric-specific head-to-head trial base

The closest thing to a pediatric-specific pivotal comparison of peak-flow-based versus symptom-based self-management is a Cochrane review of written asthma action plans (WAPs) in children, covering four trials (three RCTs and one quasi-RCT, n=355 children). It found that children using symptom-based WAPs had a lower risk of an exacerbation requiring an acute-care visit than children using peak-flow-based WAPs (RR 0.73, 95% CI 0.55-0.99; number needed to treat to prevent one acute-care visit = 9, 95% CI 5-138), and that children themselves preferred symptom monitoring over peak-flow monitoring (RR 1.21, 95% CI 1.00-1.46), though parents showed no preference (RR 0.96, 95% CI 0.18-2.11). The same review found no significant group differences in exacerbations requiring oral steroids or admission, school absenteeism, lung function, symptom score, or quality of life [3] [single-source].

A more recent pediatric RCT tested a different mechanism — peak-flow feedback as a behavioral intervention rather than an action-plan format — in 354 Latino and Black adolescents (mean age 13.2±2.2 years) recruited from Bronx, NY hospitals, comparing PEF-feedback sessions against supportive counseling, both delivered across three sessions over six weeks. At 1-month follow-up the PEF-feedback group showed greater improvement than the counseling group on underperception of airflow limitation (difference-in-differences -12.64, 95% CI -17.54 to -7.74), percent personal best PEF (+9.89, 95% CI 7.13-12.65), percent predicted FEV1 (+4.93, 95% CI 0.95-8.90), and inhaled-corticosteroid adherence (+16.02, 95% CI 7.15-24.89); most of these gains were maintained at 12 months. The same trial reports plainly: "No between-group differences existed for asthma control or health care use" [4] [single-source].

Negative and null findings: process measures move, hard outcomes mostly do not

Two independent reviews — one pediatric-only, one combining adults and children — agree qualitatively that electronic monitoring/adherence interventions raise adherence more reliably than they move clinical outcomes, though the specific point estimates below are each single-study [5][7]. A systematic review and meta-analysis of 10 RCTs of electronic adherence-monitoring devices in children (n=1,123) found the device group was 1.50 times more likely to adhere to inhalers than controls (Hedges' g=0.64, medium-to-large effect), but reports: "no significant differences were observed between the intervention and control groups for asthma exacerbations, lung function and asthma control" [5] [single-source]. A Cochrane review of digital adherence interventions — 40 RCTs, n=15,207, adults and children combined, not pediatric-only — found adherence up 14.66 percentage points (low-certainty evidence), asthma control improved (SMD 0.31, moderate-certainty), and exacerbations reduced (RR 0.53, low-certainty, only 6 of 40 trials contributing); it also found the FEV1 improvement (+3.58% predicted) fell "below 12%," which the review states is "unlikely to be clinically significant" [7] [single-source].

The one pediatric RCT in this evidence base that measured hard health-care-utilization outcomes found them moving in the opposite direction from what a monitoring product would want. In a multicenter trial of sensor-based inhaler monitoring with clinician feedback (252 caregiver-child dyads: 127 control, 125 intervention), the Asthma Control Test score rose more in the intervention arm at endline (Δ=2.2, SE=0.6, P<.01), and caregiver quality of life was directionally higher (Δ=0.3, SE=0.2, P=.1). But adjusted emergency-department-visit rates (incidence rate ratio 2.2, SE=0.5, P<.01) and hospitalization rates (incidence rate ratio 3.4, SE=1.4, P<.01) were significantly greater in the sensor-monitored arm than in the control arm at the same endline. The trial's own authors conclude that "higher health care use was observed among the intervention participants relative to the control, indicating further refinement is warranted" [6] [single-source]. This is the only pediatric trial located this pass with posted ED-visit and hospitalization outcomes for a home electronic-monitoring intervention, and it runs against, not for, the proposition that this class of device reduces acute care use.

A direct trial-registry sweep this pass (connectors trials, condition "pediatric asthma", intervention "peak flow home monitoring," 10-year window) returned zero registered trials beyond what the domain dossier's own §5 already documents (ALPACA/NCT05517096, NCT05139485, NCT06321471) — none of which has posted results.

4. Sources

[1] Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma - Summary Report 2007 — National Asthma Education and Prevention Program Coordinating Committee, Journal of Allergy and Clinical Immunology (published 2007, month/day not given in the PubMed record; accessed 2026-09-01; peak-flow-monitoring passages read from the NIH Bookshelf full-report mirror). PMID 17983880 — https://www.ncbi.nlm.nih.gov/books/NBK7230/ [guideline] [2] 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group — National Heart, Lung, and Blood Institute, Journal of Allergy and Clinical Immunology (published 2020, month/day not given in the PubMed record; accessed 2026-09-01). PMID 33280709 — https://pmc.ncbi.nlm.nih.gov/articles/PMC7924476/ [guideline] [3] Written action plans for asthma in children — Cochrane Database of Systematic Reviews (published 2006-07-19; accessed 2026-09-01). PMID 16856090 — https://pubmed.ncbi.nlm.nih.gov/16856090/ [peer-reviewed] [4] Peak Flow Feedback Intervention Improves Underperception of Airflow Limitation in Pediatric Asthma: A Randomized Clinical Trial — Annals of the American Thoracic Society (published 2025 Mar, day not given in the PubMed record; accessed 2026-09-01). PMID 39454196 — https://pubmed.ncbi.nlm.nih.gov/39454196/ [peer-reviewed] [5] Electronic adherence monitoring devices for children with asthma: A systematic review and meta-analysis of randomised controlled trials — International Journal of Nursing Studies (published 2021 Oct, day not given in the PubMed record; accessed 2026-09-01). PMID 34391027 — https://pubmed.ncbi.nlm.nih.gov/34391027/ [peer-reviewed] [6] Sensor-Based Electronic Monitoring for Asthma: A Randomized Controlled Trial — Pediatrics (published 2021 Jan, day not given in the PubMed record; accessed 2026-09-01). PMID 33386336 — https://pubmed.ncbi.nlm.nih.gov/33386336/ [peer-reviewed] [7] Digital interventions to improve adherence to maintenance medication in asthma — Cochrane Database of Systematic Reviews (published 2022-06-13; accessed 2026-09-01). PMID 35691614 — https://pubmed.ncbi.nlm.nih.gov/35691614/ [peer-reviewed]

5. Sourcing & Gaps

Well established: that the current NAEPP guideline text on monitoring method predates, and was left untouched by, the 2020 focused update rests on two documents from the same guideline body agreeing on what the update did and did not cover [1][2] — read as corroborated on that narrow point, though every specific evidence-graded recommendation quoted from [1] is still single-source. That electronic monitoring/adherence interventions raise medication adherence more reliably than they raise asthma control or reduce exacerbations is a qualitative pattern that recurs across two independent reviews with non-overlapping trial sets, one pediatric-only and one mixed-age [5][7], though each specific number is marked to its own source.

Thin: every point estimate in section 3 — the Cochrane WAP review's risk ratios and NNT [3], the PEF-feedback trial's differences-in-differences [4], the pediatric EMD meta-analysis's effect size [5], the sensor-based RCT's incidence rate ratios [6], and the mixed-age Cochrane review's pooled estimates [7] — rests on exactly one document and carries [single-source]. [7]'s population is adults and children combined, not pediatric-only; its subgroup breakdown by age was not reported in the abstract depth this pass read, so its numbers are carried forward as directional context for the pediatric-only findings in [3], [4], [5], and [6], not as pediatric findings in their own right.

Rescoped from class 3: none in this report. Every proposition here is a class 2 published guideline statement or trial/review finding; nothing here answers what a clinician, child, or caregiver would do. The nearest class-3 question in this domain — whether prescribers would adopt or families would sustain use of a monitoring device — is already addressed in the domain dossier §5/§9 via the revealed-behaviour twin of three registered pediatric home-RPM-asthma research programs, and is not re-answered here.

Out of scope: GINA's own report text was not attempted this pass (named specifically, not folded into a substitute source); the 2022 AHA/ACC/HFSA-equivalent pediatric pulmonology society statement, if one exists, was not searched; any full pediatric subgroup breakdown of [7]'s pooled estimates was not available in the abstract retrieved and was not pursued further behind a paywall.

Not searched vs. not found: A direct connectors trials sweep (condition "pediatric asthma," intervention "peak flow home monitoring," 10-year window) is a not found result — it returned zero registered trials, which is a genuine absence beyond the three already logged in the domain dossier, not an unsearched gap. GINA's report text is not searched, not not-found — no attempt was made to fetch it this pass.

[inference] Reading the sensor-based RCT's utilization finding [6] as evidence that cuts against an RPM-billed monitoring device's value proposition — rather than as a confound of that one trial's specific feedback design — is this report's own synthesis. The trial's authors call for "further refinement," not for abandoning the approach, and no second pediatric hard-outcome trial exists in this evidence base to confirm or contradict the direction.

6. Claim Candidates